Image: Pexels | Written by: Medical Companion Travel Content Team
Original articles, please do not reprint without permission
In recent years, the aging of the mainland population has been very serious, and the prevalence of Alzheimer's disease has also increased year by year. According to statistics, the number of people with Alzheimer's disease in the elderly population on the mainland has exceeded 6 million, becoming the world's first.
Rivastigmine, also known as Rivastigmine, is currently the only perdermal treatment for mild to moderate dementia caused by all patients with Alzheimer's or Parkinson's disease, and can effectively improve symptoms such as cognitive deficits associated with Alzheimer's. Kabalatin transdermal patch is a rare medicine, and today I will take you to learn more about this drug.
First, about Alzheimer's disease and the current status of treatment
Alzheimer's disease is an irreversible neurodegenerative disease that can cause damage to memory, cognition, personality, and other functions. Early detection and intervention have important clinical significance for improving symptoms and delaying disease progression.
However, there are many difficulties in the actual clinical treatment process, the existing treatment drugs are limited, the research and development of new drugs is slow, and the patient's compliance is also very poor, which is why Alzheimer's disease is known as one of the most difficult treatment areas to break through.
There are already more than 50 million people living with Alzheimer's disease worldwide, and the disease has become a major public health challenge worldwide.
Second, the mechanism of action and efficacy of carbalatin transdermal patch
Kabalatin transdermal patch is an acetylcholinesterase inhibitor of the carbamate type and is thought to promote cholinergic neurotransmission by slowing down the degradation of acetylcholine released by functionally intact cholinergic neurons. Thus, kabbalatine may have an ameliorating effect on cholinergic-mediated cognitive deficits in dementia associated with Alzheimer's disease.
Safety & Efficacy:
Foreign clinical trial studies have shown that the use of Exelon Patch (kabalatin transdermal patch) once a day can improve the memory and maintenance of daily activities in Alzheimer's patients, and the treatment effect of low-dose patch administration group is comparable to that of oral administration group, but the incidence of nausea and vomiting in patients with oral administration is 3 times that of the patch administration group. The cognitive scores in the high-dose patch-administered group were slightly higher than those in the oral administration group, and the incidence of adverse reactions was similar.
3. In 2019, Gary Bio and Dahua Pharmaceutical jointly developed the kabalatin transdermal patch in Macao and was approved for listing
In August 2019, Shanghai Gary Biopharmaceutical Co., Ltd. announced that the Rivamensa (Rivastigmine) transdermal patch developed in cooperation with Dahua Pharmaceutical has recently obtained a registration and marketing license in Macao. The kabalatin transdermal patch is an innovative transdermal dosage form of the carbalatin drug.
More than 70% of caregivers believe that the form of the patch is better than the capsule, the patient's medication compliance is better, and the disturbance to daily life is also small.
Fourth, Luye Pharmaceutical's innovative drug Lisse's Mingduo day transdermal patch was qualified for marketing in many european countries
In May 2021, Luye Pharmaceutical Group announced that its application for the listing of its self-developed innovative formulation, Leiss' Mingduo Day Transdermal Patch, has successfully passed the EU non-centralized review process. As of the date of completion of the review on 21 May 2021, the product is eligible for marketing authorization in several participating member states of the European Union.
V. Drug research and development process of Alzheimer's disease
The development of alzheimer's disease drugs is not easy, so up to now, there are relatively few drugs available to treat the disease. Many drugs are still under investigation.
In July 2018, world-renowned generic drug giant Mylan Announced the launch of Novartis' Exelon & Patch generic drug in the United States. To improve cholinergic-mediated cognitive dysfunction in patients with Alzheimer's disease.
In May 2019, Roche released data and safety findings from the Gantenerumab SCarletRoAD and Marguerite RoAD open-label extended study released by Roche showed that amyloid in the brain of Alzheimer's disease patients with or without ARIA-E continued to be significantly reduced.
In October 2019, BIOGEN and Eisai jointly announced that BIOGEN plans to submit a biologics license application for the Alzheimer's disease drug aducanumab to the FDA in early 2020, and will continue to negotiate with regulatory agencies in Europe, Japan and other regions. In November of the same year, the State Drug Administration conditionally approved the listing application of Shanghai Green Valley Pharmaceutical Co., Ltd.'s new drug for the treatment of Alzheimer's disease, Phase IX I (Ganlut sodium), for mild to moderate Alzheimer's disease and improving patients' cognitive function.
The above drugs have extraordinary significance in the development process of Alzheimer's disease drugs and are worth pondering.
VI. Conclusion
At present, the transdermal patch of carbalatin has not been listed in China, and the existing one in China is the oral reagent type of carbalatin. There is still a big gap in the Alzheimer's disease drug research and development market, and the author also expects that more good drugs will be developed in the future, which can fill this big gap and benefit the majority of Alzheimer's disease patients.